Clinical Trial Update: [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the PET tracer [18F]DASA-23 for PKM2 expression in intracranial neoplasms and glioblastoma, including healthy volunteers, has been term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Intracranial Neoplasm

Drugs mentioned

• [18F]DASA-23 (DASA-23)

Snippet

Sponsor: Guido A. Davidzon, MD, SM | Conditions: Healthy Subject, Intracranial Neoplasm | Phase 1 | Status: TERMINATED